同和药业(300636.SZ)：公司直接发美国的产品比例较低

Core Viewpoint - The company has a low proportion of direct exports to the United States, indicating that the recent tariff increases on this segment will have minimal impact on its operations [1] Group 1: Impact of Tariffs - The company's direct exports to the U.S. are limited, thus the impact of U.S. tariffs on this business segment is considered minor [1] - Indirect business may be affected by U.S. tariffs, as domestic and Indian manufacturers exporting to the U.S. are adopting a wait-and-see approach due to tariff uncertainties [1] - Further assessment is needed to evaluate the overall impact of these tariff changes on the company's operations [1]